SAWAI GROUP HOLDINGS Co., Ltd.
4887・Prime Market・Pharmaceuticals
Governance
As a company with an Audit and Supervisory Committee, the company employs a system of 8 directors in total: 5 directors who are not Audit and Supervisory Committee members (3 of whom are outside directors) and 3 directors who are Audit and Supervisory Committee members (2 of whom are outside directors). The company has introduced an executive officer system to separate decision-making from business execution, and has established a Nomination and Compensation Governance Committee to enhance the independence and transparency of the Board of Directors.
Risk Management
The Group Risk Management Committee oversees company-wide risk, identifying material risks through a two-axis evaluation of likelihood and impact. Each responsible department formulates countermeasures and monitors progress, with a structure in place to report to the Board of Directors once a year. The committee also collaborates with the Compliance Committee, Information Security Committee, and Sustainability Committee, and is focusing on preventing recurrence of quality and GMP management issues following the administrative sanctions imposed on Sawai Pharmaceutical.
Shareholder Returns
Annual dividend for FY2026 (ending March 2026) is ¥55 per share (interim ¥27 + year-end ¥28), with a payout ratio of 60.8%. For FY2027 (ending March 2027), the company forecasts ¥56 per share (interim ¥28 + year-end ¥28), with a payout ratio expected to be 34.8%. During the fiscal year, the company retired treasury shares (equivalent to ¥33,240 million).
Dividend Policy
The company aims for stable and continuous dividends, comprehensively considering the mid- to long-term profit level, DOE, and other factors. The basic policy is to pay dividends twice a year, an interim dividend and a year-end dividend. The actual annual dividend for FY2026 (ending March 2026) is ¥55 (payout ratio 60.8%, dividend on equity attributable to owners of parent of 3.6%), and the forecast for FY2027 (ending March 2027) is an annual dividend of ¥56 (expected payout ratio of 34.8%). Additionally, during the fiscal year, the company retired treasury shares held, resulting in a significant decrease in the number of treasury shares at fiscal year-end to 1,503 shares (down sharply from 16,018,103 shares at the end of the previous fiscal year).
ESG
Under its endorsement of the TCFD and TNFD frameworks, the company has set a target of reducing Scope 1+2 emissions by 46% by FY2030 (versus FY2013 levels) and achieving net zero by 2050, and is promoting energy-saving investments utilizing an Internal Carbon Price (ICP) of ¥13,500 per ton. In terms of human capital, the company is working to raise the ratio of female managers to 15% or more (target by end of FY2027) and to advance ID&E initiatives, and has integrated materiality issues—such as improving access to healthcare, ensuring quality and safety, biodiversity conservation, and strengthening corporate governance—into its medium-term management plan.
Last updated: June 24, 2026